Revenue - Additional Information (Detail) - USD ($)			1 Months Ended	3 Months Ended			6 Months Ended
	Dec. 26, 2023	Mar. 30, 2023	Jun. 30, 2023	Sep. 30, 2024	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Disaggregation Of Revenue [Line Items]
Net product revenue					$ 736,000	$ 131,454,000	$ 2,109,000	$ 132,584,000
License agreement receivable					233,000		233,000		$ 2,463,000
Deferred revenue, current portion					1,229,000		1,229,000		1,189,000
Deferred revenue, long term					1,817,000		1,817,000		$ 2,727,000
Product Revenue, Net
Disaggregation Of Revenue [Line Items]
Net product revenue					0	468,000	0	1,598,000
GlaxoSmithKline Intellectual Property
Disaggregation Of Revenue [Line Items]
License agreement contract asset					19,500,000		19,500,000
License Agreement | GlaxoSmithKline Intellectual Property
Disaggregation Of Revenue [Line Items]
Development milestones recevied			$ 25,000,000
License transfer performance obligation revenue						130,100,000		130,100,000
License Agreement | GlaxoSmithKline Intellectual Property | License Transfer
Disaggregation Of Revenue [Line Items]
Revenue recognized					700,000	131,000,000	2,100,000	131,000,000
Exclusive License And Collaboration Agreement
Disaggregation Of Revenue [Line Items]
Revenue recognized					$ 0	$ 0	$ 0	$ 0
Achivement of Threshold Upto 200 Million | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date One
Disaggregation Of Revenue [Line Items]
Sales milestone payable upon achievement of threshold limit	$ 64,000,000
Achivement of Threshold Upto 200 Million | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Two
Disaggregation Of Revenue [Line Items]
Sales milestone payable upon achievement of threshold limit	54,250,000
Achivement of Threshold Upto 200 Million | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Three
Disaggregation Of Revenue [Line Items]
Sales milestone payable upon achievement of threshold limit	46,500,000
Achivement of Threshold Upto 300 million to 500 Million | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date One
Disaggregation Of Revenue [Line Items]
Sales milestone payable upon achievement of threshold limit	45,500,000
Achivement of Threshold Upto 300 million to 500 Million | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Two
Disaggregation Of Revenue [Line Items]
Sales milestone payable upon achievement of threshold limit	45,500,000
Achivement of Threshold Upto 300 million to 500 Million | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Three
Disaggregation Of Revenue [Line Items]
Sales milestone payable upon achievement of threshold limit	39,000,000
Achivement of Threshold Upto 750 million to 1 Billion | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date One
Disaggregation Of Revenue [Line Items]
Sales milestone payable upon achievement of threshold limit	35,000,000
Achivement of Threshold Upto 750 million to 1 Billion | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Two
Disaggregation Of Revenue [Line Items]
Sales milestone payable upon achievement of threshold limit	35,000,000
Achivement of Threshold Upto 750 million to 1 Billion | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Three
Disaggregation Of Revenue [Line Items]
Sales milestone payable upon achievement of threshold limit	30,000,000
Successful Completion of Mario Study | License Agreement | GlaxoSmithKline Intellectual Property
Disaggregation Of Revenue [Line Items]
Development milestones recevied	7,350,000
Completion FURI, CARES, and NATURE Clinical Studies | License Agreement
Disaggregation Of Revenue [Line Items]
Development milestones recevied	10,000,000
Forecast | License Agreement | GlaxoSmithKline Intellectual Property
Disaggregation Of Revenue [Line Items]
Development milestones receivable				$ 10,000,000
Maximum | License Agreement | GlaxoSmithKline Intellectual Property
Disaggregation Of Revenue [Line Items]
Regulatory milestone payments receivable	49,000,000	$ 70,000,000
Commercial milestones payments receivable	57,500,000	115,000,000
Sales milestone payments receivable		242,500,000
Development milestones receivable	72,350,000	$ 75,500,000
Maximum | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date One
Disaggregation Of Revenue [Line Items]
Sales milestone payments receivable	179,500,000
Maximum | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Two
Disaggregation Of Revenue [Line Items]
Sales milestone payments receivable	169,750,000
Maximum | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Three
Disaggregation Of Revenue [Line Items]
Sales milestone payments receivable	145,500,000
Maximum | Achivement of Two Interim Milestone of Ongoing Mario Study | License Agreement | GlaxoSmithKline Intellectual Property
Disaggregation Of Revenue [Line Items]
Development milestones receivable	$ 30,000,000
Sales Revenue Net | Customer Concentration Risk | Wholesaler One
Disaggregation Of Revenue [Line Items]
Percentage of gross revenue								46.00%
Sales Revenue Net | Customer Concentration Risk | Wholesaler Two
Disaggregation Of Revenue [Line Items]
Percentage of gross revenue								26.00%
Sales Revenue Net | Customer Concentration Risk | Wholesaler Three
Disaggregation Of Revenue [Line Items]
Percentage of gross revenue								25.00%